Large-scale discovery, analysis and design of protein energy landscapes. Read more about Large-scale discovery, analysis and design of protein energy landscapes.
In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-dependent cytotoxicity. Read more about In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-dependent cytotoxicity.
Identification of novel CLK1 inhibitors by computational fragment-based ligand design, co-crystallization, chemical synthesis and structure activity relationships. Read more about Identification of novel CLK1 inhibitors by computational fragment-based ligand design, co-crystallization, chemical synthesis and structure activity relationships.
Identification and Validation of 3-Cyano-Quinoline Ligands Targeting Integrin-Linked Kinase (ILK). Read more about Identification and Validation of 3-Cyano-Quinoline Ligands Targeting Integrin-Linked Kinase (ILK).
Design and Synthesis of Pyrimidino[4,5-d]Pyrimidine-Based Compounds as Potent B-RAF V600E Inhibitors. Read more about Design and Synthesis of Pyrimidino[4,5-d]Pyrimidine-Based Compounds as Potent B-RAF V600E Inhibitors.
ABHD2 activity is not required for the non-genomic action of progesterone on human sperm. Read more about ABHD2 activity is not required for the non-genomic action of progesterone on human sperm.
A guide to selecting high-performing antibodies for ARID2 (UniProt ID: Q68CP9) for use in western blot, immunoprecipitation, and immunofluorescence. Read more about A guide to selecting high-performing antibodies for ARID2 (UniProt ID: Q68CP9) for use in western blot, immunoprecipitation, and immunofluorescence.
Kinetic Fingerprints as Mechanistic and Clinical Roadmaps Across KIT Activation States. Read more about Kinetic Fingerprints as Mechanistic and Clinical Roadmaps Across KIT Activation States.
High-throughput protein target mapping enables accelerated bioactivity discovery for ToxCast and PFAS compounds. Read more about High-throughput protein target mapping enables accelerated bioactivity discovery for ToxCast and PFAS compounds.
p21-Activated Kinase (PAK) Group I-Targeting Inhibitors Promote the Dimeric Conformation in Live Cells. Read more about p21-Activated Kinase (PAK) Group I-Targeting Inhibitors Promote the Dimeric Conformation in Live Cells.
